Login to Your Account

Morphosys, GSK Ink $586M Pact for MOR103 in RA, MS

By Cormac Sheridan
Staff Writer

Tuesday, June 4, 2013
GlaxoSmithKline plc is in-licensing MOR103, an antibody in clinical development in rheumatoid arthritis and multiple sclerosis at veteran antibody developer Morphosys AG, in return for an up-front payment of €22.5 million (US$29 million), plus another potential €423 million in milestones linked to its progress through clinical development, regulatory approval and sales.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription